Institution Directory

Clinical trials at Huntsman Cancer Institute (University of Utah)

Sites in Salt Lake City, UT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1142

Shown on this page

Current sort

Live official records

Conditions: Stroke Recurrence, Myocardial Infarction, Vascular Death, Ischemic Stroke, TIA (Transient Ischemic Attack), Stroke (CVA) or Transient Ischemic Attack, Recurrent Stroke
Interventions: Cilostazol 100 mg Tablets, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 40 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 46
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 37 more

Conditions: Type B Aortic Dissection
Interventions: TEVAR, Guideline directed medical therapy and surveillance of dissection; Procedure · Other
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more

Conditions: Posterior Fossa Ependymal Tumor
Interventions: Metformin, Planned Surgical Resection, Magnetic Resonance Imaging (MRI), Specimen Collection, MR spectroscopy (MRS); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Year to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions: Nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more

Conditions: RSV Infection
Interventions: RSVpreF, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 0 Years and older
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 81
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 30 more

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions: Carboplatin, Cisplatin, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Proton Beam Radiation Therapy; Drug · Procedure · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 79 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 178
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 128 more

Conditions: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions: Mevrometostat, Placebo, Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 127
States / cities: Huntsville, Alabama • Chandler, Arizona • Gilbert, Arizona + 89 more

Conditions: Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch, Endometrial Cancer, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
Interventions: Reiki therapy; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions: Biopsy Procedure, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tazemetostat Hydrobromide, Trametinib Dimethyl Sulfoxide; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 17
States / cities: Aventura, Florida • Coral Gables, Florida • Deerfield Beach, Florida + 11 more

Conditions: Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 12,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2034
U.S. locations: 86
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 65 more

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Atezolizumab, Cabozantinib S-malate; Biological · Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Colorectal Adenocarcinoma
Interventions: Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Quality-of-Life Assessment, Questionnaire Administration; Drug · Dietary Supplement · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1027
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 676 more

About this Huntsman Cancer Institute (University of Utah) institution page

What this page lists: ClinicalTrials.gov records that list Huntsman Cancer Institute (University of Utah) in Salt Lake City, UT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Huntsman Cancer Institute (University of Utah)

Filter and sort this campus

Live official records

Cilostazol for Prevention of Recurrent Stroke Trial

IMPRoving Outcomes in Vascular DisEase - Aortic Dissection

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

About this Huntsman Cancer Institute (University of Utah) institution page